ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sidney Chocron
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, Y.
Right arrow Articles by Kantelip, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, Y.
Right arrow Articles by Kantelip, J.-P.
Related Collections
Right arrow Myocardial protection

Ann Thorac Surg 2001;72:1985-1990
© 2001 The Society of Thoracic Surgeons

Original article: cardiovascular

Effects of L-arginine administration before cardioplegic arrest on ischemia-reperfusion injury

Yusheng Yan, MDa, Siamak Davani, MD*b, Sidney Chocron, MDa, Bernadette Kantelip, MDc, Patrice Muret, MDb, Jean-Pierre Kantelip, MDb

a Department of Cardiovascular and Thoracic Surgery, Jean Minjoz University Hospital, Besançon, France
b Department of Pharmacology, Jean Minjoz University Hospital, Besançon, France
c Department of Pathology, Jean Minjoz University Hospital, Besançon, France

Accepted for publication August 7, 2001.

* Address reprint requests to Dr Davani, Department of Pharmacology, Jean Minjoz University Hospital, 25000 Besançon, France
e-mail: davani{at}ufc-chu.univ-fcomte.fr

Background. Administration of L-arginine during reperfusion or its addition to cardioplegic solution has been shown to protect myocardium against ischemia-reperfusion injury. This study aimed at evaluating the role of L-arginine in ischemia-reperfusion injury when administered intraperitoneally 24 hours before cardioplegic arrest.

Methods. Two groups of Sprague-Dawley rats (control, n = 10; and L-arginine, n = 10) were studied in an isolated buffer-perfused heart model. Both groups were injected intraperitoneally 24 hours before ischemia. Before experimentation blood samples were collected for cardiac troponin I and cGMP analysis. In the coronary effluents, cardiac troponin I, adenosine, cyclic guanosine monophosphate, and nitric oxide metabolites were assayed.

Results. Before heart excision, serum cardiac troponin I concentrations were higher in the L-arginine than in the control group (0.037 ± 0.01 versus 0.02 ± 0.05 µg · L-1; p < 0.05). During reperfusion, cardiac troponin I release was lower in the L-arginine than in the control group (0.04 ± 0.01 versus 0.19 ± 0.03 ng · min-1; p < 0.05). The coronary flow as well as the left ventricular developed pressure were higher in the L-arginine than in the control group before ischemia and remained so throughout the experimentation.

Conclusions. These results indicate that L-arginine administered intraperitoneally 24 hours before cardioplegic arrest reduced myocardial cell injury and seems to protect myocardium against ischemia-reperfusion injury.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. H. Kown, M. A. Lijkwan, C. L. Jahncke, S. Murata, J. B. Rothbard, and R. C. Robbins
L-arginine polymers enhance coronary flow and reduce oxidative stress following cardiac transplantation in rats
J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1065 - 1070.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.